How ADT Works — and What It Actually Does to the Body

---

The vast majority of prostate cancers are driven by androgens — male hormones, primarily testosterone.

Testosterone acts as fuel for prostate cancer cells. When testosterone is present, the cancer grows. When testosterone is removed or blocked, the cancer slows down, shrinks, and in many cases becomes undetectable on standard scans and PSA tests — at least temporarily.

ADT achieves this by reducing testosterone to castrate levels — below 50 nanograms per decilitre, which is roughly the level achieved by surgical removal of the testes. Most ADT today uses injections rather than surgery to achieve this.

The most commonly used injections are LHRH agonists — drugs like leuprolide (Lupron) and goserelin (Zoladex). These work by flooding the pituitary gland's LHRH receptors, which paradoxically causes the gland to stop sending signals to the testes to produce testosterone.

Within two to four weeks of the first injection, testosterone levels fall to near zero. PSA — which is produced by prostate cancer cells and correlates closely with tumour activity — typically follows, dropping significantly within the first one to three months.

The PSA response rate to first-line ADT in hormone-sensitive prostate cancer is approximately 90 to 95 percent. For most men, it is striking — a PSA that was 50, 100, or higher can fall to under 1 within three months of starting treatment.

ADT Drugs Available in India — LHRH, Anti-Androgens and Newer Agents

---

India's major cancer hospitals stock every class of hormone therapy agent used globally.

The significant advantage for international patients is that many of these drugs are available as licensed Indian generics at prices that bear no resemblance to what they cost in Western markets.

LHRH agonists — the backbone of ADT

Leuprolide (Lupron) and goserelin (Zoladex) are the most widely used LHRH agonists. Both are given as subcutaneous or intramuscular depot injections that release the drug slowly over one, three, or six months.

In India, generic versions of leuprolide are available from multiple manufacturers at USD 80 to 150 per monthly injection — compared to USD 800 to 1,500 in the United States.

The drug is the same molecule, made to the same pharmacological standard. The price difference is entirely structural.

One practical note for international patients: LHRH agonists cause an initial testosterone surge — called a flare — in the first week after the first injection.

This temporary rise in testosterone can cause a short-term worsening of bone pain or urinary symptoms in men with advanced disease.

To prevent this, a short course of an anti-androgen tablet — bicalutamide — is started one week before the first injection and continued for two to four weeks afterwards. This is standard practice at all major Indian oncology centres.

LHRH antagonists — degarelix and relugolix

LHRH antagonists work differently from agonists. They block LHRH receptors directly without the initial testosterone flare.

Degarelix (Firmagon) achieves castrate testosterone levels within three days of the first injection — significantly faster than LHRH agonists.

It is the preferred option when very rapid testosterone suppression is needed — for example in a man with spinal cord compression from bone metastases where delayed testosterone reduction could be dangerous.

Relugolix (Orgovyx) is an oral LHRH antagonist — a daily tablet rather than an injection. It also avoids the flare and recovers testosterone faster when stopped.

Recent data suggests a possible cardiovascular advantage over injectable LHRH agonists. It is available at major Indian centres.

Anti-androgens — bicalutamide and flutamide

Anti-androgens block testosterone at the receptor level inside the cancer cell — they do not reduce testosterone production but prevent the cell from using it.

Bicalutamide is the most widely used. It is taken as a daily oral tablet.

As a standalone treatment for localised disease in older men who wish to preserve sexual function, bicalutamide monotherapy is an alternative to castration-level ADT — though it is generally considered less effective for metastatic disease.

In India, bicalutamide 50mg tablets cost approximately USD 10 to 20 per month. In the United States, the same drug costs USD 60 to 150 per month. For a drug used for months or years, even this smaller saving adds up.

Who Needs Hormone Therapy — and for How Long

---

The role of ADT in prostate cancer treatment depends entirely on the stage and risk group of the disease.

Localised low-risk disease — ADT is generally not needed

Men with low-risk localised prostate cancer — Gleason 6, PSA below 10, stage T1 or T2a — on active surveillance or having definitive local treatment do not routinely require ADT.

If this is your situation and an oncologist in your home country has recommended hormone therapy, it is worth asking why — and whether a second opinion is worth seeking.

Not all prostate cancer needs ADT and starting it unnecessarily exposes you to significant side effects without a clear clinical benefit.

Intermediate-risk disease — short-course ADT with radiation

For favourable intermediate-risk disease treated with radiation, short-course ADT of four to six months is standard.

ADT is typically started four to eight weeks before radiation begins, continued during the radiation course, and then stopped two to four months after radiation ends. The total duration is four to six months from first injection to last.

For unfavourable intermediate-risk disease, some guidelines now recommend extending ADT to 18 months in combination with radiation.

High-risk and locally advanced disease — long-course ADT

For high-risk localised or locally advanced disease — Gleason 8 to 10, stage T3 or T4, PSA above 20 — long-course ADT of 18 to 36 months is standard when radiation is given.

Multiple large trials have shown that extending ADT duration in this group significantly improves both disease-free survival and overall survival. The EORTC 22863 and RTOG 85-31 trials, among others, established this as the evidence base that current guidelines are built on.

For men with locally advanced disease who are not having radiation — for example elderly or frail men who are not fit for intensive treatment — ADT alone is a reasonable approach, understanding that it is controlling rather than curing the disease.

Metastatic hormone-sensitive prostate cancer

For men with metastatic disease — cancer that has spread to bones, lymph nodes, or other organs — ADT is the primary systemic treatment and is continued indefinitely.

Current guidelines strongly recommend adding either abiraterone or enzalutamide to ADT from the outset for metastatic hormone-sensitive disease — this combination has been shown to significantly extend life compared to ADT alone in multiple large randomised trials.

This is the combination where India's drug pricing creates its most extraordinary advantage.

A man who needs ADT plus abiraterone indefinitely would pay USD 5,000 to 7,000 per month for the abiraterone alone in the United States. In India the same molecule as a quality-assured generic costs USD 100 to 300 per month.

Biochemical recurrence after surgery or radiation

When PSA rises after primary treatment — a sign the cancer may have returned — salvage treatment options include salvage radiation to the prostate bed, ADT, or a combination.

For men with confirmed local recurrence or high-risk features on PSMA PET-CT, early ADT combined with salvage radiation is increasingly the recommended approach.

The duration of ADT in this setting varies — typically 18 to 24 months — depending on the PSA level and imaging findings.

Side Effects of ADT — What to Genuinely Prepare For

---

The side effects of ADT are real and they deserve an honest description — not a reassuring list that minimises what men actually experience.

Some men sail through ADT with minimal disruption to their daily lives. Others find certain side effects — particularly fatigue and hot flushes — genuinely difficult.

Most side effects are manageable with the right preparation, monitoring, and lifestyle adjustments. And for short-course ADT of four to six months, most reverse within six to twelve months of stopping.

Hot flushes

Hot flushes are the most universally reported side effect of ADT. They affect approximately 75 percent of men on castration-level therapy.

They feel exactly like what women describe during menopause — a sudden wave of heat, often starting in the chest or neck and moving upward, sometimes with sweating. They can occur multiple times a day and at night, disrupting sleep.

Management options include low-dose medroxyprogesterone, cyproterone acetate, or venlafaxine. Physical measures — light clothing, cool environments, avoiding triggers — help many men.

Most find the flushes become more predictable and manageable after the first few months.

Fatigue

Fatigue is common and tends to build gradually over the first few months of ADT rather than appearing suddenly at the start.

The most effective thing a man can do to combat ADT fatigue is regular aerobic exercise. Multiple studies have shown that men who exercise during ADT have significantly lower fatigue scores than those who do not.

This is one of the most robust and actionable findings in the quality-of-life literature for prostate cancer treatment.

Loss of libido and sexual function

With testosterone near zero, sexual desire falls significantly in most men within the first month of ADT. Erectile function also diminishes.

For short-course ADT, libido and erections typically recover within six to eighteen months of stopping treatment, though full recovery is not guaranteed for all men, particularly those over 65.

For long-course or continuous ADT, permanent reduction in sexual function should be expected and discussed with a partner before starting treatment.

Bone density loss

Testosterone is important for maintaining bone density. ADT accelerates bone loss at roughly 2 to 3 percent per year — a rate that increases fracture risk significantly over years of treatment.

All men on ADT for more than six months should take calcium 1,000mg and vitamin D 800 to 1,000 IU daily as standard.

A baseline DEXA bone density scan before starting long-course ADT, and a repeat scan every one to two years, allows monitoring and triggers bisphosphonate treatment if significant loss occurs.

Metabolic changes and cardiovascular risk

ADT increases body fat — particularly visceral abdominal fat — and reduces lean muscle mass. It raises blood glucose and cholesterol levels and increases the risk of metabolic syndrome.

These changes increase cardiovascular risk, and men with pre-existing heart disease or diabetes need closer monitoring during long-course ADT. Regular exercise and dietary attention to reduce refined carbohydrates and processed foods are the most effective mitigation strategies.

Cognitive and mood effects

Some men on ADT report difficulty concentrating, word-finding problems, and low mood or mild depression.

These effects are real but variable — many men notice nothing of significance cognitively.

If they occur, acknowledging them and discussing them with your oncologist matters — both because depression is treatable and because cognitive changes that are severe or worsening should be assessed.

Abiraterone and Enzalutamide — the Drugs That Change the Cost Equation

---

Abiraterone (Zytiga) and enzalutamide (Xtandi) are two of the most significant advances in prostate cancer treatment of the past two decades.

Both are oral tablets taken daily. Both extend life significantly in metastatic prostate cancer — both hormone-sensitive and castration-resistant disease. Both are now guideline-recommended as standard of care for metastatic disease.

And in the United States and United Kingdom, both are extraordinarily expensive. This is where India changes everything for many international patients.

How abiraterone works

Abiraterone acetate blocks an enzyme called CYP17A1, which is responsible for producing androgens not only in the testes but in the adrenal glands and within the tumour cells themselves.

Standard LHRH injections suppress testicular testosterone but leave adrenal and intratumoral androgen production intact. Abiraterone suppresses all of these sources simultaneously — creating a more complete androgen blockade.

It is always given alongside low-dose prednisone (5mg twice daily) to prevent mineralocorticoid excess — a side effect of CYP17A1 blockade. Without prednisone, abiraterone causes fluid retention, hypertension, and low potassium.

How enzalutamide works

Enzalutamide is a next-generation androgen receptor antagonist.

Where older anti-androgens like bicalutamide block the androgen receptor partially and incompletely, enzalutamide blocks it far more powerfully — and also prevents the receptor from moving into the cell nucleus where it activates growth signals.

It is effective in both hormone-sensitive and castration-resistant metastatic disease. The ENZAMET and ARCHES trials demonstrated significant overall survival benefit when enzalutamide is added to standard ADT in metastatic hormone-sensitive disease from the outset.

The India generic pricing reality

Both abiraterone and enzalutamide are available in India as quality-assured licensed generics manufactured by reputable Indian pharmaceutical companies — Sun Pharma, Cipla, Dr Reddy's, and others.

These are not counterfeit drugs or unregulated alternatives. They are manufactured to Indian central drug authority standards and in many cases by the same companies that supply generics to NHS England.

The pricing difference is not a small discount. It is a structural transformation.

Abiraterone at USD 100 to 300 per month versus USD 5,000 to 7,000 in the United States means a man who needs two years of treatment saves between USD 112,000 and USD 160,000 — a number that changes what treatment is financially feasible.

Drug	India (generic)	USA (branded)	2-year saving vs USA
Abiraterone acetate	USD 100–300/month	USD 5,000–7,000/month	~USD 112,000–160,000
Enzalutamide	USD 200–500/month	USD 5,500–8,000/month	~USD 124,000–180,000
Bicalutamide 50mg	USD 10–20/month	USD 60–150/month	~USD 1,000–3,000
Leuprolide (LHRH, monthly)	USD 80–150/month	USD 800–1,500/month	~USD 15,000–30,000
Docetaxel chemotherapy (per cycle)	USD 200–600/cycle	USD 3,000–8,000/cycle	~USD 15,000–45,000 (6 cycles)

Cost of Hormone Therapy in India vs UK and USA

---

The cost comparison for hormone therapy drugs between India and Western markets is not a modest saving — it is a fundamental difference in what treatment is financially possible for most patients.

In the United States, a man with metastatic prostate cancer needing ADT plus abiraterone faces drug costs of USD 6,000 to 8,500 per month — over USD 80,000 per year — even before hospital and monitoring costs are included.

In India, the same treatment costs USD 200 to 450 per month. For a patient in Nigeria, Kenya, Bangladesh, or anywhere without public funding for these drugs, India is not just cheaper — it is the only place treatment is financially reachable.

The consultation to initiate treatment — oncology review, staging confirmation, blood tests, first injection, and drug prescription — typically costs USD 300 to 600 in total at a major Indian cancer centre.

This is the upfront investment that unlocks months or years of affordable ongoing treatment.

Read the full cost breakdown: Prostate cancer treatment cost in India — complete guide for international patients →

Starting in India, Continuing at Home — How It Works in Practice

---

The most practical ADT model for most international patients is to start treatment in India — where the consultation, staging workup, and first injection or prescription are arranged — and then continue the treatment from home.

This works because the ongoing management of stable ADT does not require a specialist hospital visit every month. It requires a PSA blood test every three months, a testosterone level check periodically, and an injection or tablet refill.

In most countries, a GP or local oncologist can administer LHRH injections and monitor PSA — once the treatment plan has been established and documented by an Indian specialist.

GAF Healthcare provides every patient with a full treatment summary written for their local doctor, including the drug name and dose, the monitoring schedule, and what findings should prompt urgent specialist review.

Carrying medication home — what is legally permitted

Indian law permits patients to carry a personal supply of prescribed medication when travelling internationally. Most countries allow importation of a personal supply — typically one to three months — when accompanied by a valid prescription and a doctor's letter.

The specific rules vary by country. GAF Healthcare advises on the import regulations of your home country before you travel and provides the documentation — prescription, doctor's letter, and a translated summary if required — needed to carry your supply legally.

For abiraterone and enzalutamide, which are oral tablets, carrying a three-month supply in original pharmacy packaging with a prescription is standard practice for GAF Healthcare patients returning to Nigeria, Kenya, the UAE, Bangladesh, and the United Kingdom.

Ongoing monitoring — what to watch for

PSA should be checked every three months during the first two years of treatment. A falling or undetectable PSA is the expected and desired response.

A PSA that stops falling, stabilises at a high level, or starts rising again on ADT is the signal that warrants an oncology review — either remotely with your Indian specialist or with a local oncologist.

Testosterone level should be checked at three months to confirm castrate levels have been achieved, and periodically thereafter. A testosterone above 50 ng/dL on LHRH therapy suggests the drug may not be working adequately or may have been administered incorrectly.

Blood pressure and blood glucose should be monitored every three to six months on long-course ADT — particularly in men also taking abiraterone, which raises blood pressure and has a small risk of worsening glucose control.

"My husband was told he needed abiraterone indefinitely. In the UK it would have cost us £2,800 every month — even with some NHS support. We found GAF Healthcare and flew to Delhi. The oncologist reviewed everything, confirmed the diagnosis and the treatment plan, and wrote a letter for our GP. We came home with three months of abiraterone in our bags. It cost us less than two weeks of what we would have paid here. Our GP gives the injection. We WhatsApp the Indian doctor with every PSA result."

— Mrs. F. O., wife of a 71-year-old Nigerian patient · metastatic prostate cancer · ADT + abiraterone initiated at Medanta, March 2025